Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senators probe kickback allegations against Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Sens. Charles Grassley, R-Iowa, chair of the Senate Finance Committee, and Herb Kohl, D-Wis., chair of the Senate Special Committee on Aging, are asking Medtronic to provide details about alleged incentives the company provided to physicians in exchange for the use and promotion of the firm's spine products, including off-label use of the Infuse bone graft replacement. The allegations stem from a 2002 lawsuit by former Medtronic legal counsel Ami Kelley, which was sealed by a federal judge but reported on in September and October by the Wall Street Journal. Among the charges cited by Kohl were "improper, if not illegal, payments by Medtronic to surgeons and physicians." Those cited by Grassley included adding doctors' names to patents and providing royalties for devices they did not help to develop. The lawsuit led to a $40 million settlement agreement between Medtronic and the government, which is being challenged in federal court by former Medtronic travel manager Jacqueline Kay Poteet, who said the amount was too low ("1The Gray Sheet" July 24, 2006, p. 3)

You may also be interested in...

Medtronic To Track Sales Contacts, Pay $40 Mil. To Settle Kickback Probe

Medtronic will begin recording all transactions between its spine product sales personnel and physicians as part of a settlement agreement with the U.S. Department of Justice

UK IVDs Firms Working Flat Out On COVID-19 Tests, As Govt Promises Test Capacity Increase

Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts